Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
BrainCells logo — Pioneering biopharmaceutical solutions to enhance neuron gro...

BrainCells

Pioneering biopharmaceutical solutions to enhance neuron growth and address CNS disorders with advanced clinical-stage programs

Founded 2003 Debt Financing Total: $73.68M Biotechnology, Health Care +1

General Information

Company Name BrainCells
Founded Year 2003
Founders / Decision Makers
Team member
Industries Biotechnology, Health Care, Medical Devices
Funding Stage Debt Financing
Social

BounceWatch is an independent company data service, not affiliated with BrainCells. To contact BrainCells, visit braincellsinc.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does BrainCells compare?

A PDF of BrainCells and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting BrainCells soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About BrainCells

BrainCells is a biopharmaceutical company founded in 2003 and headquartered in San Diego, California. The company's slogan - "Pioneering biopharmaceutical solutions to enhance neuron growth and address CNS disorders with advanced clinical-stage programs" - underscores its focus on developing innovative solutions for central nervous system (CNS) diseases. BrainCells is dedicated to creating compounds that promote the growth of new neurons for conditions such as major depressive disorder (MDD), treatment-resistant depression (TRD), and potentially Alzheimer’s disease (AD). The company's product line includes BCI-838 and BCI-632, which work by enhancing synaptic glutamate through the inhibition of the mGlu2/3 auto-receptor. Additionally, BrainCells is actively building a robust pipeline of clinical-stage programs to target unmet medical needs in mood disorders, psychoses, cognitive issues, brain repair, and other CNS disorders. The company has received a $1.98M Debt Financing investment on 11 January 2012. This investment reflects the confidence of the investing party in BrainCells' innovative approach and the potential of its products to address critical unmet needs in the treatment of CNS disorders. With its strong focus on biotechnology and healthcare, BrainCells is positioned to make significant contributions to the advancement of treatments for neurological conditions, making it an intriguing prospect for venture capital firms seeking opportunities in the biopharmaceutical sector.

Business keywords: Biopharmaceuticals, Neuroscience, Central Nervous System Disorders, Neuron Growth, Clinical-stage Programs, Major Depressive Disorder, Treatment-resistant Depression, Alzheimer's Disease, BCI-838, BCI-632, Synaptic Glutamate, mGlu2/3 Auto-receptor, San Diego, Drug Development, Neurological Disorders

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Debt Financing $1.98M -
11 Jan 2012
Debt Financing $4.00M -
01 Aug 2011
Series B $20.00M 2
New Enterprise Associates
New Enterprise Associates, Alexandria Real Estate Equities
01 Apr 2008
Series B $30.00M 6
Technology Partners Bay City Capital Neuro Ventures
Technology Partners, Bay City Capital +4
01 Mar 2008
Series A $17.70M 2
Bay City Capital Oxford Bioscience Partners
Bay City Capital, Oxford Bioscience Partners
15 Jul 2005

BrainCells Alternatives & Competitors

View All Alternatives
BrainCells vs
Acadia Pharmaceuticals
Acadia Pharmaceuticals United States

Acadia is trailblazing breakthroughs in neuroscience to elevate life.

Post-IPO Equity
1028 employees
Biotechnology, Health Care
BrainCells vs
Umecrine Cognition AB
Umecrine Cognition AB Sweden

A novel and safe approach for treating cognitive disorders

Convertible Note
11 employees
Biotechnology, Health Care
BrainCells vs
Emalex Biosciences
Emalex Biosciences United States

Improving people's lives impacted by central nervous system disorders through meaningful scientific...

Series D
54 employees
Biopharma, Biotechnology
Also compare with: BrainCells vs Bionomics Ltd Bionomics Ltd View all alternatives

FAQ About BrainCells

Pioneering biopharmaceutical solutions to enhance neuron growth and address CNS disorders with advanced clinical-stage programs
BrainCells was founded in 2003.
BrainCells operates in Biotechnology, Health Care and Medical Devices. Its work centres on Biopharmaceuticals, Neuroscience, Central Nervous System Disorders and Neuron Growth.
BrainCells has completed 5 funding rounds, raising a total of $73.68M. The latest funding stage is Debt Financing.
Top alternatives and competitors to BrainCells include Acadia Pharmaceuticals, Umecrine Cognition AB, Emalex Biosciences, Bionomics Ltd, Alzamend Neuro. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
BrainCells and Acadia Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for BrainCells, https://bouncewatch.com/company/braincells, updated 12 September 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout